<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04966325</url>
  </required_header>
  <id_info>
    <org_study_id>LG-GDCL008</org_study_id>
    <nct_id>NCT04966325</nct_id>
  </id_info>
  <brief_title>Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects</brief_title>
  <official_title>A Single-Dose, Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Way Crossover Study to Evaluate the Effect of LC350189 on the QTc (Corrected QT) Interval in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Chem</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, single-center, randomized, partially double-blind, placebo- and positive&#xD;
      controlled, 4-way crossover study to evaluate the effect of a therapeutic and a&#xD;
      supratherapeutic dose of LC350189 on the QTcF in healthy male and female subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>4-way cross over</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>LC350189 and placebo will be administered in a double blind, double-dummy manner. Moxifloxacin will be administered open-label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The placebo-corrected change from baseline in QTcF</measure>
    <time_frame>Before dosing (Baseline) through 24 hours after the dose on Day 1 in each treatment period</time_frame>
    <description>QTcF will be analyzed using concentration-QT (cQT) modeling</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The placebo-corrected change from baseline in HR (heart rate)</measure>
    <time_frame>Before dosing (Baseline) through 24 hours after the dose on Day 1 in each treatment period</time_frame>
    <description>HR will be evaluated at each postdose time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The placebo-corrected change from baseline in PR</measure>
    <time_frame>Before dosing (Baseline) through 24 hours after the dose on Day 1 in each treatment period</time_frame>
    <description>PR will be evaluated at each postdose time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The placebo-corrected change from baseline in QRS</measure>
    <time_frame>Before dosing (Baseline) through 24 hours after the dose on Day 1 in each treatment period</time_frame>
    <description>QRS will be evaluated at each postdose time point</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Hyperuricemia</condition>
  <condition>Gout</condition>
  <condition>Qt Interval, Variation in</condition>
  <arm_group>
    <arm_group_label>Treatment T (Therapeutic dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of 200 mg LC350189 (1 × 200 mg tablet) and 2 × placebo tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment ST (Supratherapeutic dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of 600 mg LC350189 (3 × 200 mg tablets).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment P (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single oral dose of 3 × placebo tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment M (positive control)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single oral dose of moxifloxacin 400 mg (1 × 400 mg tablet; open label)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LC350189 200mg</intervention_name>
    <description>Subject will receive an LC350189 200mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)</description>
    <arm_group_label>Treatment T (Therapeutic dose)</arm_group_label>
    <other_name>LC350189 (therapeutic dose)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subject will receive a Placebo as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)</description>
    <arm_group_label>Treatment P (Placebo)</arm_group_label>
    <other_name>Placebo control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin 400mg</intervention_name>
    <description>Subject will receive a Moxifloxacin 400mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)</description>
    <arm_group_label>Treatment M (positive control)</arm_group_label>
    <other_name>Positive control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LC350189 600mg</intervention_name>
    <description>Subject will receive an LC350189 600mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)</description>
    <arm_group_label>Treatment ST (Supratherapeutic dose)</arm_group_label>
    <other_name>LC350189 (supratherapeutic dose)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject is 18 to 55 years of age, inclusive, with a body mass index (BMI) 18 to 33&#xD;
             kg/m2, inclusive, at screening.&#xD;
&#xD;
          -  The subject is considered by the investigator to be in good general health as&#xD;
             determined by medical history, clinical laboratory test results, vital sign&#xD;
             measurements, 12-lead ECG results, and physical examination findings at screening.&#xD;
&#xD;
          -  The subject is able to provide written informed consent and agrees to comply with all&#xD;
             protocol requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has a history of risk factors for torsades de pointes, including&#xD;
             unexplained syncope, known long QT syndrome, heart failure, myocardial infarction, or&#xD;
             angina.&#xD;
&#xD;
          -  The subject has a family history of long QT syndrome, Brugada syndrome, or sudden&#xD;
             death.&#xD;
&#xD;
          -  The subject has a resting HR of &lt;40 bpm or &gt;100 bpm when vital signs are measured at&#xD;
             screening or check-in.&#xD;
&#xD;
          -  The subject has history or presence of unstable cardiovascular disease, including&#xD;
             myocardial infarction, cardiac arrhythmia, or cerebrovascular disease (eg,&#xD;
             cerebrovascular accident/stroke or transient ischemic attack).&#xD;
&#xD;
          -  The subject has a history of other acute or chronic cardiovascular disease or coronary&#xD;
             revascularization surgery (eg, coronary artery bypass graft, percutaneous transluminal&#xD;
             coronary angioplasty).&#xD;
&#xD;
          -  The subject uses a cardiac pacemaker.&#xD;
&#xD;
          -  The subject has a history of any other medical, psychological, or social condition&#xD;
             that, in the opinion of the investigator or the medical monitor, would prevent the&#xD;
             subject from fully participating in the study, would represent a concern for study&#xD;
             compliance, or would constitute a safety concern to the subject.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Younghwan Jang</last_name>
    <phone>82-2-6987-4154</phone>
    <email>younghj@lgchem.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PPD</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 28, 2021</study_first_submitted>
  <study_first_submitted_qc>July 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2021</study_first_posted>
  <last_update_submitted>July 18, 2021</last_update_submitted>
  <last_update_submitted_qc>July 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>To be determined</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

